Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647022 | 1.00 | RAB9A (0.45) | RAB9ANPC1TAS1R3TAS1R1CYP3A4 | |
| SCHEMBL1581789 | 0.89 | ALDH1A1 (0.44) | RAB9ANPC1POLBALDH1A1HTT | |
| SCHEMBL1581786 | 0.89 | ALDH1A1 (0.44) | RAB9ANPC1POLBALDH1A1HTT | |
| SCHEMBL1581896 | 0.88 | ALDH1A1 (0.43) | RAB9ANPC1POLBALDH1A1HTT | |
| SCHEMBL1581894 | 0.88 | ALDH1A1 (0.43) | RAB9ANPC1POLBALDH1A1HTT | |
| SCHEMBL4265493 | 0.86 | RAB9A (0.37) | RAB9ANPC1POLBALDH1A1HTT | |
| SCHEMBL4265499 | 0.86 | RAB9A (0.37) | RAB9ANPC1POLBALDH1A1HTT | |
| SCHEMBL2022051 | 0.85 | RAB9A (0.43) | RAB9ANPC1TAS1R3TAS1R1POLB | |
| SCHEMBL2026768 | 0.85 | RAB9A (0.43) | RAB9ANPC1TAS1R3TAS1R1POLB | |
| SCHEMBL2024245 | 0.85 | RAB9A (0.43) | RAB9ANPC1TAS1R3TAS1R1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | BIZZARO FRED T | 2005-11-24 | — | — | US | disclosed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | RAB9A 4777/4885NPC1 3972/4885TAS1R3 4143/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | RAB9A 4752/4885NPC1 4000/4885TAS1R3 4068/4885 |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | RAB9A 4777/4885NPC1 3972/4885TAS1R3 4143/4885 |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | RAB9A 4777/4885NPC1 3972/4885TAS1R3 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.